4.4 Article

MUSCLE PATHOLOGY GRADE FOR FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY BIOPSIES

期刊

MUSCLE & NERVE
卷 52, 期 4, 页码 521-526

出版社

WILEY
DOI: 10.1002/mus.24621

关键词

clinical trials; DUX4; facioscapulohumeral muscular dystrophy; muscle pathology; pathology grade

资金

  1. National Institutes of Health [1PO1NS069539-01]
  2. Fields Center for FSHD and Neuromuscular Research
  3. University of Rochester CTSA of the National Center for Research Resources [UL1 RR024160]
  4. National Center for Advancing Translational Sciences of the National Institutes of Health
  5. Muscular Dystrophy Association
  6. CTSA grant from NCATS [KL2TR000119]

向作者/读者索取更多资源

Introduction: As we move toward planning for clinical trials in facioscapulohumeral muscular dystrophy (FSHD), a better understanding of the clinical relationship with morphological changes in FSHD muscle biopsies will be important for stratifying patients and understanding post-therapeutic changes in muscle. Methods: We performed a prospective cross-sectional study of quadriceps muscle biopsies in 74 genetically confirmed FSHD participants (64 with FSHD type 1 and 10 with FSHD type 2). We compared a 12-point muscle pathology grade to genetic mutation, disease severity score, and quantitative myometry. Results: Pathology grade had moderate correlations with genetic mutation (rho = -0.45, P < 0.001), clinical severity score (rho = 0.53, P < 0.001), disease duration (rho = 0.31, P = 0.03), and quantitative myometry (rho = -0.47, P < 0.001). We found no difference in the frequency of inflammation between FSHD types 1 and 2. Conclusions: The pathology grade of quadriceps muscle may be a useful marker of disease activity in FSHD, and it may have a role in stratification for future clinical trials.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据